AEG vs JPM

The Advanced Deterministic Scorecard reveals a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a seemingly attractive valuation with a P/E of 8.47 well below sector average and a current price below the Graham Number of $11.87, earnings volatility is extreme—recent YoY EPS growth is -3075% and Q/Q EPS growth is -1170%, signaling severe deterioration. Dividend strength is solid at 70/100 with a 5.76% yield and sustainable 44.48% payout ratio, but insider sentiment is weak at 40/100 and technical trend is deeply bearish at 10/100. Combined with erratic earnings surprises averaging -745.99% over the last four quarters, the stock appears fundamentally deteriorating despite surface-level value appeal.

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.